Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
No biomarker
Cancer:
Merkel Cell Carcinoma
Regimen:
(cisplatin + etoposide IV)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
NCCN
Published date:
10/02/2019
Excerpt:
Merkel Cell Carcinoma: Preferred regimen...Useful in certain circumstances as clinical judgment dictates for patients with contraindications to checkpoint immunotherapy...Cisplatin±Etoposide
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login